Targeted genomic profiling of solid tumours from blood
A high-precision multi-biomarker test using blood samples to extract circulating tumour DNA (ctDNA) to detect somatic variants across 118 genes with high sensitiviy and specificity.
Insight TSB – liquid biopsy for solid tumours
A targeted blood-based test designed for analysis of key oncogenes, ongoing monitoring and affordability.
What it is:
The InsightTSB test analyses a targeted set of cancer-related genes from a blood sample, providing clear insight into tumour changes over time, with the same emphasis on clarity and UK trial context.
What it is for:
Designed for people who:
- Wish to track disease progression or molecular changes over time, or
- Want more affordable access to key tumour genomics to explore what else might exist beyond routine care
What it includes:
The InsightTSB is a targeted product, that analyses clinically significant genes selected based on NCCN, ASCO, ESMO, and FDA
guidelines, including:
- Single Nucleotide Variants (SNVs) and Insertion-Deletion (InDels) across 118 genes
- Fusions in 15 genes
- Tumour fraction estimate (TFx)
What it does not include:
In order to keep the cost of the InsightTSB down it does not include some additional features available in our comprehensive InsightCSB test:
- Copy Number Variants (CNVs)
- Microsatellite Instability (MSI)
- Tumour Mutational Burden (TMB)
Why it is different:
- Broader coverage and better sensitivity than comparable tests
- UK-focused clinical trial matching, explained in context
- A clear, human-readable summary – not just technical findings
Price: £2,200
The TSB panel analyses clinically significant genes selected based on NCCN, ASCO, ESMO, and FDA guidelines.
SNVs & InDels Panel (118 Genes Total)
118 genes for SNVs and InDels, with coverage tiered as follows:
● Complete Coding Region (CCR) Coverage (73 Genes):
ABL1, AKT1, ALK, APC, AR, ARAF, ARID1A, ARID1B, ATM, ATRX, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CDK12, CDKN2A, CHEK1, CHEK2, CSF1R, CTNNB1, EGFR, ERBB2, ERCC2, ESR1, FANCL, FGFR1, FGFR2, FGFR3, FOXL2, HNF1A, HRAS, IDH1, IDH2, INPP4B, KIT, KRAS, MET, MLH1, MSH2, MSH6, MUTYH, NF1, NRAS, NTRK1, NTRK3, PALB2, PDGFRA, PIK3CA, PMS2, POLD1, POLE, PPP2R2A, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RAD54L, RB1, RET, ROS1, SMAD4, SMARCB1, SRC, STK11, TP53, TSC1, TSC2, VHL
● Hotspot Region Coverage (45 Genes):
ABL2, ATR, BAP1, C11orf65, CCND1, CDK4, CDX2, DDR2, ERBB3, ERBB4, EZH2, FBXW7, FGFR4, FLT3, FOXA1, GATA3, GNA11, GNAQ, GNAS, JAK1, JAK2, JAK3, KDM5C, KDM6A, KEAP1, MAP2K2, MAPK1, MPL, MTOR, MYC, MYCN, MYD88, NF2, NPM1, PBRM1, PTPN11, RAF1, RHEB, RHOA, RIT1, SETD2, SF3B1, SMO, SPOP, TERT
● Specific Mutation Note:
The panel is explicitly validated to include coverage for MET exon 14 skipping mutations.
Combined Full Gene List (118 Genes – SNVs & InDels):
● A: ABL1, ABL2, AKT1, ALK, APC, AR, ARAF, ARID1A, ARID1B, ATM, ATR, ATRX
● B: BAP1, BARD1, BRAF, BRCA1, BRCA2, BRIP1
● C: C11orf65, CCND1, CDH1, CDK12, CDK4, CDKN2A, CDX2, CHEK1, CHEK2, CSF1R, CTNNB1
● D: DDR2
● E: EGFR, ERBB2, ERBB3, ERBB4, ERCC2, ESR1, EZH2
● F: FANCL, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FOXA1, FOXL2
● G: GATA3, GNA11, GNAQ, GNAS
● H: HNF1A, HRAS
● I: IDH1, IDH2, INPP4B
● J: JAK1, JAK2, JAK3
● K: KDM5C, KDM6A, KEAP1, KIT, KRAS
● M: MAP2K1, MAP2K2, MAPK1, MET, MLH1, MPL, MSH2, MSH6, MTOR, MUTYH, MYC, MYCN,
MYD88
● N: NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK3
● P: PALB2, PBRM1, PDGFRA, PIK3CA, PMS2, POLD1, POLE, PPP2R2A, PTCH1, PTEN, PTPN11
● R: RAD51B, RAD51C, RAD51D, RAD54L, RAF1, RB1, RET, RHEB, RHOA, RIT1, ROS1
● S: SETD2, SF3B1, SMAD4, SMARCB1, SMO, SPOP, SRC, STK11
● T: TERT, TP53, TSC1, TSC2
● V: VHL
Fusions Panel (15 Genes Total)
This panel analyses 15 genes for clinically significant fusions and rearrangements.
● ALK, BRAF, EGFR, ERBB2
● FGFR1, FGFR2, FGFR3, FGFR4
● MET, NRG1, NTRK1, NTRK2
● NTRK3, RET, ROS1
Ready to book a test?
To find out if this or any of our genomic tests are right for you, please book a free discovery call below
Understanding the RareCan Blood-Based Cancer Genomic Test
What is this test?
RareCan’s InsightTSB test is a genomic (DNA-based) test designed to look for genetic changes in cancer using a simple blood sample. Tumours can release tiny fragments of DNA into the bloodstream. This is called circulating tumour DNA (ctDNA).
By analysing ctDNA, this test can provide information about the genetic features of a cancer without needing a tissue biopsy, or alongside one if tissue testing has already been done.
What does the test look for?
The test examines:
- Small changes in genes (mutations) including Single Nucleotide Variants (SNVs) and Insertion-Deletion (InDels) across 118 genes
- Gene fusions involving 15 genes
These features may help doctors understand:
- how a cancer behaves,
- whether certain treatments or clinical trials might be relevant,
- how a tumour’s genetics change over time.
How is the test done?
- A blood sample is taken at a clinic or in your home
- The sample is sent to a genetics laboratory.
- DNA fragments in the blood are analysed using advanced sequencing technology.
- A report is produced and shared with you and your healthcare professional.
What can the results tell me?
The test may:
- identify genetic changes linked to your cancer,
- show that no reportable changes were detected,
- identify changes whose significance is not yet fully understood,
- occasionally be unable to produce a result due to technical reasons.
Your doctor will explain what the results mean in the context of your overall medical care.
Important limitations to understand
- Not all cancers release enough DNA into the blood. A normal result does not rule out cancer or genetic changes.
- The test does not detect every possible cancer mutation.
- Some DNA changes found in blood can come from normal blood cells rather than the tumour.
- The test cannot on its own decide treatment and should not replace medical advice or other tests.
Will this test tell me which treatment I will get?
Not necessarily. While the test may highlight genetic features linked to certain treatments or trials, it does not guarantee:
- access to a specific medicine,
- NHS availability,
- insurance approval,
- or that a treatment will work.
Who should I talk to about my results?
Always discuss your results with your doctor or specialist, who can explain what they mean for you and what steps, if any, should be taken next
Other Genetic Tests
RareCan offers more than one type of genomic test. To see what else is available, click on the button below.
About our tests
- Our liquid biopsy tests work by analysing cell-free DNA (cfDNA) circulating in your blood to identify and characterise tumour-derived fragments (circulating tumour DNA, or ctDNA).
- Our tissue-based tests work by analysing tumour DNA from samples stored by your hospital following biopsy or surgery.
- The tests use Next Generation Sequencing (NGS) on high throughput Illumina platforms to provide a genomic profile of your cancer.
- Our tests are extensively validated, accredited by the American College of Pathologists (CAP) and performed in an ISO 15198 accredited laboratory.
- Analysis and reporting is undertaken as per international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified mutation database for variant interpretation and reporting.
- The output from the test is a report highlighting genetic variants found, providing information for clinicians on the potential relevance of any variants, and listing out clinical trials that might be treatment options based on the genomic profile of your cancer.
Regulatory information / disclaimer
- RareCan Insight genomic tests are registered with the Medicines and Healthcare products Regulatory Agency (MHRA) as Class 1 in vitro diagnostic medical devices.
- They are intended for use by healthcare professionals for the qualitative identification of specific somatic variants in circulating tumour DNA (ctDNA) extracted from human whole blood or tumour DNA (tDNA) extracted from tumour tissue samples.
- The tests are intended to support clinicians in identifying potential clinical trials for which you may be eligible.
- The sample collection kits are intended for use by qualified phlebotomists and are not intended for patient self-testing or self-sampling.
- Results must be interpreted by a qualified healthcare professional in conjunction with your full clinical history, other diagnostic test results, and relevant clinical guidelines.
- The results are not intended to be used as the sole basis for treatment decisions, and further confirmatory testing may be required.
Stay connected
Whether you’re looking for clinical trials, exploring cancer research studies, or simply wanting to understand your cancer diagnosis or treatment options better, these RareCan resources are here to guide you during your cancer treatment journey.
For the latest news, research updates, patient stories, and expert insights delivered straight to your inbox, register for the RareCan newsletter.